|Published:||Oct 22, 2013 9:24 AM EDT|
|Updated:||Oct 22, 2013 9:24 AM EDT|
WASHINGTON (AP) - An experimental hepatitis C drug from Johnson & Johnson appears to be slightly more effective at eliminating the virus than currently available treatments, though federal safety reviewers say it also causes rash and sunburn in some patients.
The Food and Drug Administration posted its review of simeprevir online ahead of a public meeting Thursday where experts will vote on whether to recommend the drug's approval.
More than 3 million people in the United States have Hepatitis C, a blood-borne disease linked to 15,000 deaths a year. The drugs currently used to treat the virus cure about 65 to 75 percent of people after a year of treatment.
FDA said simeprevir cured 80 percent of patients who had not previously been treated for the disease.
(Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)
- Invasive cockroach found in NYC can take the cold
- Big storm dumps snow on East Coast, travel dicey
- 3 headliners cancel music performances at SeaWorld
- Obama to pay tribute to Mandela in South Africa
- Senate Dems push Obama nominees, GOP bides time
- Study: Erratic TV violence ratings fail parents
- Senators: Put cameras on train tracks, engineers
- Congress ready to extend ban on plastic firearms
- Ex-San Diego mayor to be sentenced for harassment